Danshensu

Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

Product Specifications

CAS Number

[76822-21-4]

Product Name Alternative

Dan shen suan A; Salvianic acid A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Keap1-Nrf2; NF-κB; Reactive Oxygen Species (ROS) ; SARS-CoV

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Danshensu.html

Purity

98.59

Solubility

DMSO : < 1 mg/mL|H2O : 5 mg/mL (ultrasonic)

Smiles

OC1=C(C=CC(C[C@H](C(O)=O)O)=C1)O

Molecular Formula

C9H10O5

Molecular Weight

198.17

Precautions

H302, H315, H319, H335

References & Citations

[1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43 (4) :771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne) . 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Natural Products

Clinical Information

No Development Reported

Citation 01

Breast Cancer Res Treat. 2024 Dec;208 (3) :657-671.|Cancer Immunol Immunother. 2025 Jun 30;74 (8) :256.|J Tradit Complement Med. 2025 Feb 7;15 (4) :434-445.|Phytomedicine. 2023 May:113:154743.|Eur J Pharmacol. 2025 Feb 1:177296.